Analgesia for Patients with Substance Abuse Disorders. Lisa Jennings CN November 2015

Similar documents
Medications in the Treatment of Opioid Use Disorder: Methadone and Buprenorphine What Really Are They?

WR Fentanyl Symposium. Opioids, Overdose, and Fentanyls

Opioid Agonists. Natural derivatives of opium poppy - Opium - Morphine - Codeine

@FeliciaJCox. Caring for the person with addiction in the acute pain setting. Felicia Cox FRCN MSc RN

Fentanyls and Naloxone. Opioids, Overdose, and Naloxone

Opioids Research to Practice

Slide 1. Slide 2. Slide 3. Opioid (Narcotic) Analgesics and Antagonists. Lesson 6.1. Lesson 6.1. Opioid (Narcotic) Analgesics and Antagonists

Substitution Therapy for Opioid Use Disorder The Role of Suboxone

What is an opioid? What do opioids do? Why is there an opioid overdose crisis? What is fentanyl? What about illicit or bootleg fentanyls?

OPIOIDS AND NON-CANCER PAIN

Dr Alistair Dunn. General Practitioner Whangarei

Module Two: Pharmacotherapies for Opioid Substitution Treatment

Opioids Research to Practice

OST. Pharmacology & Therapeutics. Leo O. Lanoie, MD, MPH, FCFP, CCSAM, ABAM, MRO

An overview of Medication Assisted Treatment (MAT) and acute pain management on MAT

Controlled Substance and Wellness Agreement

PAIN & ANALGESIA. often accompanied by clinical depression. fibromyalgia, chronic fatigue, etc. COX 1, COX 2, and COX 3 (a variant of COX 1)

Opioids Research to Practice

Prescription Opioid Addiction

BASIC VOLUME. Elements of Drug Dependence Treatment

OP01 [Mar96] With regards to pethidine s physical properties: A. It has an octanol coefficient of 10 B. It has a pka of 8.4

SUBOXONE (buprenorphine and naloxone) sublingual film (CIII) IMPORTANT SAFETY INFORMATION

Opioid Use Disorders as a Brain Disease Why MAT is so important. Ron Jackson, M.S.W., L.I.C.S.W.

Agonists: morphine, fentanyl Agonists-Antagonists: nalbuphine Antagonists: naloxone

Methadone Maintenance

Acute Pain NETP: SEPTEMBER 2013 COHORT

Benzodiazepines. Benzodiazepines

LONG TERM PHARMACOTHERAPY OF OPIOID DEPENDENCE

The Patient with an Addiction

Substances under Surveillance

niap Terms and Definitions

Choose a category. You will be given the answer. You must give the correct question. Click to begin.

Developed and Presented by Randall Webber, MPH, CADC JRW Behavioral Health Services

Main Questions. Why study addiction? Substance Use Disorders, Part 1 Alecia Schweinsburg, MA Abnromal Psychology, Fall Substance Use Disorders

Opioids- Indica-ons, Equivalence, Dependence and Withdrawal Methadone Maintenance (OST) Paul Glue

POLICY DOCUMENT. CG/pain management in opioid dependency/03/15. Associate Director of Pharmacy

ten questions you might have about tapering (and room for your own) an informational booklet for opioid pain treatment

Pain Management for Adult sickle cell disease patients: Information for patients, relatives and carers

Buprenorphine pharmacology

Acute pain management in opioid tolerant patients. Muhammad Laklouk

Prescription Pain Management. University of Hawai i Hilo Pre- Nursing Program NURS 203 General Pharmacology Danita 1 Narciso Pharm D

Drugs Used In Management Of Pain. Dr. Aliah Alshanwani

Information on Specific Drugs of Abuse

SUMMARY OF PRODUCT CHARACTERISTICS FOR BENZODIAZEPINES AS ANXIOLYTICS OR HYPNOTICS

Module II Opioids 101 Opiate Opioid

Optimizing Suboxone in Opioid Addicts

Medication Assisted Treatment. MAT Opioid dependence/addiction Opioid treatment programs OTP Regulation of OTP Office Based Treatment

OPIOIDS. Testing and Interpretation

Objectives. 1. Review controversy 2. Pathophysiology 3. Indications for Use 4. Adverse Effects 5. How Patients Access

Opioid Review and MAT Clinic CDC Guidelines

Managing long term opioids and hypnotics. Dr Ravneet Batra Consultant Liaison Psychiatrist Western General Hospital, Edinburgh

Opioids Research to Practice

Steven Prakken MD Director Medical Pain Service Duke Pain Medicine

OPIOIDS FOR PERSISTENT PAIN: INFORMATION FOR PATIENTS

Opioid Pharmacology. Dr Ian Paterson, MA (Pharmacology), MB BS, FRCA, MAcadMEd. Consultant Anaesthetist Sheffield Teaching Hospitals

Long term pharmacotherapy for Alcohol Dependence: Anti Craving agents

Policy on Pharmacological Therapies Practice Guidance Note Reducing Dosing Errors with Opioid Medicines V04

Opioid rotation or switching may be considered if a patient obtains pain relief with one opioid and is suffering severe adverse effects.

What is pregabalin? Pregabalin tablets. Pregabalin misuse. National Drug Treatment Centre Research. Administration

Acknowledgements: What it is What it s not. Cannabis Evidence Series. Evidence-informed decision-making

M0BCore Safety Profile. Active substance: Bromazepam Pharmaceutical form(s)/strength: Tablets 6 mg FR/H/PSUR/0066/001 Date of FAR:

MEDICATION MANAGEMENT AGREEMENT

Opioid Overdose Epidemic A Crises and Opportunity

Specific Drugs of Abuse

Pain management. Coleman Palliative Care Conference: February 2016 Josh Baru MD Stacie Levine MD

Clinical Guidelines and Procedures for the Use of Naltrexone in the Management of Opioid Dependence Abbreviated Version

WITHDRAWING FROM BUPRENORPHINE THERAPY

PALLIATIVE CARE PRESCRIBING FOR PATIENTS WHO ARE SUBSTANCE MISUSERS

Buprenorphine: An Introduction. Sharon Stancliff, MD Harm Reduction Coalition September 2008

Opioids: Use, Abuse and Cause of Death. Jennifer Harmon Assistant Director - Forensic Chemistry Orange County Crime Laboratory

POST OPERATIVE PAIN MANAGEMENT: PAIN AND COMPLICATIONS

VOLUME C. Pharmacological Treatment for Drug Use Disorders Drug Treatment for Special Populations

ROSC & MAT II: Opioid Treatment Services

Drug & Alcohol Detox:

Multi Modal Analgesia

Understanding the Impact of Drugs on Children. Jackie McReynolds Washington State University

Prescribing Framework for Naltrexone in Relapse Prevention (Opioid Dependence)

BEHAVIOURAL SCREENING OF DRUGS HYPNOTICS/SEDATIVES

Zopiclone Orion. Date: , Version 1.2 PUBLIC SUMMARY OF THE RISK MANAGEMENT PLAN

Unit II Problem 7 Pharmacology: Substance Abuse, Dependence and Addiction

SW OREGON OPIOID SUMMIT. Medication Assisted Recovery for Opioid Use Disorder. Gregory S. Brigham, Ph.D. Adapt / SouthRiver CHC / Compass

The Art of being Human

12/14/2018. Disclosures. Buprenorphine. Drug-Receptor Interactions. Affinity

SHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR OPIOID DEPENDENCE

CONTROLLED SUBSTANCE (NARCOTIC) AGREEMENT

MAT - ICAAD 2018 Ron Jackson, MSW, LICSW

Live A Life Above The Influence!

Federal Trafficking Penalties (As of January 1, 1996)

Opioids. October 29, Addiction Medicine Review Course CSAM, Newport Beach, CA

Clinical pharmacological aspects of heroin and fentanyl overdoses

INFORMED CONSENT FOR OPIOID TREATMENT FOR NON-CANCER/CANCER PAIN Texas Pain and Regenerative Medicine

Long term treatment for opioid dependence Antagonist therapy

6/6/2018. Nalbuphine: Analgesic with a Niche. Mellar P Davis MD FCCP FAAHPM. Summary of Advantages. Summary of Advantages

Opioids. Sergio Hernandez, MD

H NDS-ONHealth. Prescription Drug Abuse. Drug overdose death rates in the United States have more than tripled since 1990 and have never been higher.

Pain and its Treatments. Our Goals: Understand: What is pain and what causes it? 2. What are different types of pain? 3. How do opioid drugs work?

3/26/14. Opiates PSY B396 ALCOHOL, ALCOHOLISM, & DRUG ABUSE. Early History Cont d. Early History. Opiate Use in the 19th century. Technology Advances

SHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR ALCOHOL DEPENDENCE INDICATION

Subject: Pain Management (Page 1 of 7)

History Of Medical Cannabis

Transcription:

Analgesia for Patients with Substance Abuse Disorders Lisa Jennings CN November 2015

Definitions n Addiction: A pattern of drug use characterised by aberrant drug-taking behaviours & the compulsive use of a substance in order to experience it s psychic effects, or to avoid the effects of it s absence (withdrawal). There is continued use despite the risk of physical, psychological or social harm to the user.

n Physical Dependence: A physiological adaptation to a drug characterised by the emergence of a withdrawal (abstinence) syndrome if the drug is abruptly stopped, reduced in dose, or antagonised.

n Tolerance: A decrease in sensitivity to opioids, resulting in less effect from the same dose, or the need for progressively larger doses to maintain the same effect. n Pseudo addiction: Drug-seeking behaviour caused by a need for better pain relief.

Addiction to Opioids n Develops due to more than just exposure to a drug n Genetic reasons n Socioeconomic factors n Psychological factors n Used to stop pain, both physical & emotional n Euphoria

Methods of Treatment n Cold Turkey withdrawal (Risky) n Harm minimisation approach by Federal Government since 1985 n Move patients off of Heroin onto Methadone since 1969 n Buprenorphine since 2000

Withdrawal Syndromes CNS Depressants n Alcohol Anxiety, agitation, restlessness, sleep disturbances, N&V, hallucinations, confusion, disorientation & seizures. 12-48hrs onset following last intake. n Benzodiazepines Similar Signs + Symptoms to ETOH. Severe abdominal cramping Onset 1-5 days following last dose. n Nicotine GIT disturbances, irritability, difficulty in concentrating, increased appetite Onset ~ 24 hrs from last intake

Opioid Receptors n Mu- µ- activation produces analgesia, sedation, respiratory depression & constipation n Kappa-К- activation produces analgesia, pupil constriction & resp. depression n Delta-δ activation is likely to produce analgesia

Withdrawal Syndromes CNS Stimulants n Cocaine, Ice, Speed - Associated with a psychological, rather than a physical dependence - Withdrawal symptoms more related to affect (mood) rather than physical symptoms (irritability, aggression, sedation, somnolence)

Opioid Withdrawal Symptoms n Anxiety n Nausea & Vomiting n Runny nose, watery eyes n Aches & Pain n Muscle Cramps n The greater the doses used and the faster the onset of the Opioid of preference: the longer and more severe the withdrawal

Methadone n Long acting synthetic opioid agonist n Rapidly absorbed, peak levels 2 to 4 hrs, half life 15 to 40 hours n Metabolised by the liver, excreted by kidneys n No significant metabolites n Dose accumulation occurs, 5 days to steady state

Methadone n Doses 60 to 80 mg once daily, no higher than 150 mg n Persistent Pain doses are bd n Has some effects at NMDA receptor- useful for neuropathic pain n If diverted and injected more intense high

Buprenorphine n Semi synthetic Opioid n Partial agonist at mu receptor n Antagonist at kappa receptor n High affinity and binds tightly top mu and delta receptors n If injected will antagonise opioid from mu receptor leading to a withdrawal n Patches are for persistent pain patients

Treating Acute Pain in these Patients n Analgesic adjuvants, Paracetamol, NSAIDS, Ketamine & Local Anaesthetics n Continue Opioid substitution regimen as prescribed n IV pain protocol, may need larger dose n Doctors to verify prescription n Opioids as charted, may require larger doses

Treating acute Pain cont n Be realistic about what you can achieve, you will not be able to remove all pain n Keep it Clinical! q Nursing Process, q Document. n Don t judge!

A word of warning n Pain Perception is likely to be enhanced in this group. n May report higher than expected pain scores, often due to opioid-induced sensitisation to pain as well as psychosocial & emotional factors n Opioid Induced Hyperalgesia = opioid receptors worn-out + pain receptors become over-stimulated n No endorphins n Very difficult to treat pain in this group!

Interesting Facts n Approx. 7.5% of prescriptions of s8 are for Drug replacement therapy. n High abuse potential of prescribed Opioids n 15% of Australians used an illicit drug in 2014

References n n n n n Corke P, 2013, Postoperative Pain Management, Australian Prescriber, vol 36, no 6 Henning R, 2015, Opioid dependency: Patients that make your heart sink Macintyre P & Schug S, 2007, Acute Pain Management A practical guide, Elsevier, Sydney Miller P 2001, A Critical Review of the Harm Minimization Ideology in Australia, Critical public health, vol.11, no 2, pp167-178 http://www.druginfo.adf.org.au/topics/quick-statistics http://www.druginfo.adf.org.au